News

BioMed SA eyes new road map to greater economic wins

BioMed SA President Ann Stevens (Photo by Lyndsey Johnson) By W. Scott Bailey, San Antonio Business ...

Diabetes, Infectious Diseases Early Focus of San Antonio Biomed Plan

David Holley, Xconomy Texas —  San Antonio — [Updated 12/14/17, 11:54 p.m. See below.] ...

Industry Publications

The Mission

The Mission is published by the University of Texas Health Science Center.

UTSA Discovery

UTSA Discovery is published annually for the Office of the Vice President for Research by the Office ...

News
Private Firm and Nonprofit Team Up in Unusual Relationship
October 7, 2014

SAN ANTONIO - BioBridge Global (BBG), a nonprofit organization, and StemBioSys Inc. (SBS), a development-stage biomedical company in the emerging field of stem cell and regenerative medicine, are pleased to announce the grand opening of a new pilot manufacturing laboratory on the BBG campus.

In a collaboration agreement, BBG constructed lab space inside its headquarters building for use by StemBioSys, which will conduct research and product development activities using its patented procedures involving various types of adult stem cells. StemBioSys was founded in 2010 to develop technology, first created at the University of Texas Health Science Center - San Antonio (UTHSC) by SBS cofounder Dr. Xiao-Dong Chen, that enables the isolation and expansion of stem cells for medical research, diagnostic and therapeutic applications.

"It's very unusual for a nonprofit organization to carve out space for a for-profit entity, but for all the right reasons, it made sense not only for us and StemBioSys but also for the city of San Antonio and UTHSC," said Linda Myers, BioBridge Global CEO. "It truly is a government-nonprofit-private entity-university mutually beneficial arrangement. It's a synergistic relationship that focuses on regenerative medicine, which is part of the future for BioBridge Global as well as the San Antonio biomedical community."

In 2013, the City Council voted to invest $200,000 in StemBioSys through a grant to the San Antonio Economic Development Corporation.

"Once StemBioSys expands and outgrows the space, BBG will be left with a world-class facility in which to continue our own research or manufacturing," Myers said.

In the partnership, BioBridge Global builds on an already-established relationship with StemBioSys that began in 2012. At that time, BBG's founding affiliate, the South Texas Blood & Tissue Center - which houses the Texas Cord Blood Bank - established an agreement to provide SBS researchers with cord blood cells. Cord blood units that are ineligible for the public cord blood bank registry are used for research.

"Because BioBridge Global is growing exponentially in the arena of cell-based research, it seemed logical - as a biomedical startup - for us to partner with them and explore that horizon together," said Bob Hutchens, CEO of StemBioSys. "San Antonio is on the cusp of becoming a world leader in regenerative medicine, and we believe our arrangement with BioBridge Global will position StemBioSys to continue our breakthrough research and bring new technologies to market. Through strong local partnerships like this, San Antonio can make a global impact within the regenerative medicine sector." Hutchens also noted, "Our founders, Dr. Steven Davis and Dr. Xiao-Dong Chen, have been exploring potential collaborations with BioBridge Global since StemBioSys' founding. All of us at StemBioSys are excited about this important milestone in our relationship with BBG."

StemBioSys plans to begin operations on BioBridge Global's campus on or about Oct. 18 and locate there for the next several years as the company continues to grow and mature. The new laboratory comprises approximately 1,000 square feet and will be cGMP (Current Good Manufacturing Practices) compliant.

About StemBioSys: StemBioSys Inc., a privately held San Antonio-based biomedical company, manufactures and develops innovative, advanced stem cell technologies to meet the promise of regenerative medicine in a surging global market. Its patented and proprietary technology platforms - licensed from the University of Texas Board of Regents - overcome key obstacles to creating clinically useful stem cell therapies. Visit stembiosys.com.

About BioBridge Global: BioBridge Global (BBG) is a San Antonio, Texas-based nonprofit organization that offers diverse services in regenerative medicine, blood banking and biologic testing. Its subsidiaries - the South Texas Blood & Tissue Center, QualTex Laboratories and GenCure - house several centers that provide products used in regenerative medicine treatment and research, including cellular therapies, umbilical cord blood and tissue services as well as blood and plasma product testing for clients in the United States and worldwide. BBG is an outgrowth of the South Texas Blood & Tissue Center, which has a proud history of serving the South Texas region for more than 40 years. BBG is committed to supporting groundbreaking research, addressing unmet clinical needs and enabling the development and commercialization of novel biotechnology products. Visit biobridgeglobal.org.

 

Stay informed. Subscribe to BioMed SA news alerts.